Brief: LSL Pharma Q3 Revenue CAD 2.512 Mln
29/11/2023 12:40
Nov 29 (Reuters) - LSL Pharma Q3 net income CAD -762 thousand. * Q3 EPS CAD -0.01 * Q3 revenue CAD 2.512 million * Q3 adjusted EBITDA CAD 96 thousand
Recent news on LSL Pharma
See all newsBrief: LSL Pharma Group Announces CFO Transition
Canada's LSL Pharma Q2 revenue surges on acquisition boost, eye-drop launches
Brief: Lsl Pharma Group Reports Record Revenues And Second Quarter 2026 Results
Brief: LSL Pharma Group Successfully Obtained U.S. FDA Certification For The Manufacturing Of Ophthalmic Ointments For Commercialization In The United States
Brief: LSL Pharma Group Announces Closing Of The Acquisition Of Juno Otc And Final $2M Closing Of Upsized $12M Offering